KS900: A hypoxia-directed, reductively activated methylating antitumor prodrug that selectively ablates O6-alkylguanine-DNA alkyltransferase in neoplastic cells

Biochemical Pharmacology

Volumn 81, Issue 10, 2011, Pages 1201-1210

  Baumann, Raymond P ^a   Ishiguro, Kimiko ^a   Penketh, Philip G ^a   Shyam, Krishnamurthy ^a   Zhu, Rui ^a   Sartorelli, Alan C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

1,2 Bis(sulfonyl)hydrazines; KS900; O6 alkylguanine DNA alkyltransferase; Onrigin ; Oxygen deficient cells

Indexed keywords

1,2 BIS(METHYLSULFONYL) 1 METHYL 2 [[1 (4 NITROPHENYL)ETHOXY]CARBONYL]HYDRAZINE; 1,2 BIS(METHYLSULFONYL) 1 METHYLHYDRAZINE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE INHIBITOR; ANTINEOPLASTIC AGENT; GUANINE; KS 90; KS 900; LAROMUSTINE; ONRIGIN; OXIDOREDUCTASE; OXYGEN; PRODRUG; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CATALYST; CELL SURVIVAL; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DRUG DECOMPOSITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; HYPOXIA; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL HYPOXIA; CELL LINE, TUMOR; CRICETINAE; CRICETULUS; HUMANS; HYDRAZINES; METHYLATION; MICE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; OXIDOREDUCTASES; PRODRUGS; SULFONAMIDES;

EID: 79955478096     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.02.019     Document Type: Article

References (39)

1. P.W. Vaupel, S. Frinak, and H.I. Bicher Heterogeneous oxygen partial pressure and pH distribution in C3H mouse mammary adenocarcinoma Cancer Res 41 1981 2008 2013 (Pubitemid 11114612)
2. P. Vaupel, F. Kallinowski, and P. Okunieff Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors Cancer Res 49 1989 6449 6465 (Pubitemid 20008770)
3. M. Höckel, and P. Vaupel Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects J Natl Cancer Inst 9 2001 266 276 (Pubitemid 32219813)
4. Q.T. Le, N.C. Denko, and A.J. Giaccia Hypoxic gene expression and metastasis Cancer Metastasis Rev 23 2004 293 310 (Pubitemid 38881813)
5. R. Bristow, and R. Hill Hypoxia, DNA repair and genetic instability Nature 8 2008 180 192
6. J. Pouyssegur, F. Dayan, and N.M. Mazure Hypoxia signaling in cancer and approaches to enforce tumor regression Nature 441 2006 437 443 (Pubitemid 44050138)
7. N. Denko Hypoxia, HIF1 and glucose metabolism in the solid tumor Nat Rev Cancer 8 2008 705 713
8. 2 availability on human cancer Nat Rev Cancer 8 2008 967 975
9. S. Loges, M. Mazzone, P. Hohensinner, and P. Carmeliet Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited Cancer Cell 15 2009 167 170
10. M. Mazzone, D. Dettori, R. Oliveira, S. Loges, T. Schimdt, and B. Jonckx Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization Cell 136 2009 1 13
11. J.T. Erler, K.L. Bennewith, M. Nicolau, N. Dornhofer, C. Kong, and Q. Le Lysyl oxidase is essential for hypoxia-induced metastasis Nature 440 2006 1222 1226
12. J.T. Erler, K.L. Bennewith, T.R. Cox, G. Lang, D. Bird, and A. Koong Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche Cancer Cell 15 2009 35 44
13. A.C. Sartorelli Therapeutic attack of hypoxic cells of solid tumors: presidential address Cancer Res 48 1988 775 778 (Pubitemid 18061861)
14. K. Shyam, P.G. Penketh, M. Shapiro, M.F. Belcourt, R.H. Loomis, and S. Rockwell Hypoxia-selective nitrobenzyloxycarbonyl derivatives of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines J Med Chem 42 1999 941 946
15. H.A. Seow, P.G. Penketh, K. Shyam, S. Rockwell, and A.C. Sartorelli 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl] hydrazine: an anticancer agent targeting hypoxic cells Proc Natl Acad Sci 102 2005 9282 9287 (Pubitemid 40923555)
16. R.P. Baumann, P.G. Penketh, K. Ishiguro, K. Shyam, Y.L. Zhu, and A.C. Sartorelli Reductive activation of the prodrug 1,2-bis(methylsulfonyl)-1-(2- chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine (KS119) selectively occurs in oxygen-deficient cells and overcomes O(6)-alkylguanine-DNA alkyltransferase mediated KS119 tumor cell resistance Biochem Pharmacol 79 2010 1553 1561 PMCID: PMC2885764
17. P.G. Penketh, K. Shyam, and A.C. Sartorelli Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas Biochem Pharmacol 59 2000 283 291 (Pubitemid 30001755)
18. F. Giles, D. Thomas, G. Garcia-Manero, S. Faderl, J. Cortes, and S. Verstovsek A phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia Clin Cancer Res 10 2004 2908 2917 (Pubitemid 38619664)
19. R.P. Baumann, H.A. Seow, K. Shyam, P.G. Penketh, and A.C. Sartorelli The antineoplastic efficacy of the prodrug cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation Oncol Res 15 2005 313 325 (Pubitemid 43074226)
20. K. Ishiguro, H.A. Seow, P.G. Penketh, K. Shyam, and A.C. Sartorelli Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine Mol Cancer Ther 5 2006 969 976 PMCID: PMC2680221 (Pubitemid 43724597)
21. T. Mekhail, S. Gettinger, G. Blumenschein, R. Axelrod, M. Haingentz, and M.J. Guarino A phase II trial of VNP40101M in patients with relapsed or refractory small cell lung cancer (SCLC) with or without brain metastases J Clin Oncol 25 2007 7724
22. F. Giles Laromustine: the return of alkylators to non-myeloablative therapy for AML Leuk Res 33 2009 1022 1023
23. A. Pigneux Laromustine, a sulfonyl hydrolyzing alkylating prodrug for cancer therapy IDrugs 12 2009 39 53
24. 6-alkylguanine-DNA alkyltransferase W.E. Cohn, K. Moldave, Progress in Nucleic Acid Research and Molecular Biology 1995 San Diego Academic Press 167 223
25. S.L. Gerson MGMT: its role in cancer aetiology and cancer therapeutics Nat Rev Cancer 4 2004 296 307 (Pubitemid 38525285)
26. L. Liu, and S.L. Gerson Targeted modulation of MGMT: clinical implications Nat Rev Clin Cancer Res 12 2006 328 331 (Pubitemid 43166117)
27. 6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy Cell Mol Life Sci 67 2010 3663 3681
28. 6- benzylguanine followed by carmustine in patients with advanced cancer Clin Cancer Res 6 2000 3025 3031 (Pubitemid 30637724)
29. D. Rizzieri, S. LoRusso, W. Tse, K. Khan, A. Advani, and J. Moore Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia Clin Lymphoma Myeloma Leuk 10 2010 211 216
30. 6-benzylguanine to the protein Anal Biochem 383 2008 44 51 PMCID: PMC2773450
31. K. Shyam, P.G. Penketh, A.A. Divo, R.H. Loomis, C.L. Patton, and A. Sartorelli Synthesis and evaluation of 1,2,2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents J Med Chem 33 1990 2259 2264 (Pubitemid 20236675)
32. R. Baumann, P. Penketh, H. Seow, K. Shyam, and A. Sartorelli Generation of oxygen deficiency in cell culture using a two-enzyme system to evaluate agents targeting hypoxic tumor cells Radiat Res 170 2008 651 660 PMCID: PMC266728110
33. S. Rockwell In vivo-in vitro tumor systems: new models for studying the response of tumors to therapy Lab Anim Sci 27 1977 831 851 (Pubitemid 8255715)
34. M.F. Belcourt, W.F. Hodnick, S. Rockwell, and A.C. Sartorelli The intracellular location of NADH:cytochrome b5 reductase modulates the cytotoxicity of the mitomycins to Chinese hamster ovary cells J Biol Chem 273 1998 8875 8881 (Pubitemid 28176169)
35. K.M. Holtz, S. Rockwell, M. Tomasz, and A.C. Sartorelli Nuclear overexpression of NADH:cytochrome b5 reductase activity increases the cytotoxicity of mitomycin C (MC) and the total number of MC-DNA adducts in Chinese hamster ovary cells J Biol Chem 278 2003 5029 5034 (Pubitemid 36801012)
36. K. Ishiguro, Y.L. Zhu, K. Shyam, P.G. Penketh, R.P. Baumann, and A.C. Sartorelli Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase Biochem Pharmacol 80 2010 1317 1325
37. P.G. Penketh, R.P. Baumann, K. Ishiguro, K. Shyam, H.A. Seow, and A.C. Sartorelli Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating species Leuk Res 32 2008 1546 1553 PMCID: PMC2888535
38. 6-alkylguanine-DNA alkyltransferase J Med Chem 47 2004 3887 3891 (Pubitemid 38900353)
39. 6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death J Pharmacol Exp Ther 311 2004 585 593 (Pubitemid 39391543)